Search Results - malcolm+brock

4 Results

Sort By:

Diagnostic and therapeutic target for primary dysautonomia

Value Proposition:· Diagnostic target for broad primary dysautonomia screening.· Broadly applicable therapeutic target for symptom relief in primary and secondary dysautonomia patients.Technology DescriptionResearchers at Johns Hopkins have identified a potential diagnostic and therapeutic target for patients with primary dysautonomia....

Published: 5/10/2024 | Inventor(s): Malcolm Brock, Frank Bosmans

Keywords(s):

Category(s): Clinical and Disease Specializations > Neurology, Clinical and Disease Specializations > Cardiovascular, Technology Classifications > Therapeutic Modalities, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities > Small Molecules

Diagnostics and Therapeutic Monitoring Using AI Analysis Integrated with Magnetic Resonance Spectral Patterns of Biofluids

Unmet needPancreatic ductal adenocarcinoma (PDAC) is the most frequent form of pancreatic cancer, with a survival rate of less than 10% at five years largely due to late-stage diagnosis1. Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, which is the leading cause of cancer death worldwide, primarily due to metastatic disease2....

Published: 5/10/2024 | Inventor(s): Meiyappan Solaiyappan, Santosh Bharti, Zaver Bhujwalla, Michael Goggins, Malcolm Brock

Keywords(s):

Category(s): Technology Classifications > Diagnostics

Low Dose Adjuvant Epigenetic Modifiers Inhibit Cancer Lung Metastases through Disruption of the Myeloid Environment in Pre-metastatic Niches

Unmet NeedCancer recurrence, even following complete surgical resection, remains a large unmet clinical problem. In non-small cell lung cancer (NSCLC) patients, recurrence following surgery remains 30-70%, and the five-year survival rate remains 23% with over 140,000 deaths occurring each year. Recurrence post-surgery can be driven by a number of factors,...

Published: 5/9/2024 | Inventor(s): Malcolm Brock, Zhihao Lu

Keywords(s): Antagonists/Inhibitors, Cancers, Chemotherapy/Chemotherapy, Combination, Disease Indication, Non-novel, Predicted Novelty, Small Molecules, Therapeutic Matter, Therapeutic Substance, Therapeutics, Therapy Type

Category(s): Clinical and Disease Specializations > Oncology > Lung Cancer, Technology Classifications > Therapeutic Modalities > Small Molecules

Using DNA Methylation Markers To Create a Molecular Staging Paradigm for Solid Malignancies and To Predict Cancer Recurrence and Patient Survival

Technology: Currently, cancer recurrence in solid malignancies occurs in many patients after complete curative surgery despite no additional histological evidence of remaining cancer outside the area of resection, especially in the surrounding lymph nodes. It is believed that in patients with recurrent disease, micrometastases reside that are undetectable...

Published: 5/9/2024 | Inventor(s): James Herman, Stephen Baylin, Malcolm Brock

Keywords(s): Biomarker, Cancers, Clinical Diagnostics, Disease Indication, Epigenetic, In Vitro Diagnostics, Methylation, Risk Stratification

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Oncology, Technology Classifications > Computers, Electronics & Software > Precision Medicine Tools, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Computers, Electronics & Software, Technology Classifications > Diagnostics